Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma

Mohammed A. Aljama; M. Hasib Sidiqi; Arjun Lakshman; Angela Dispenzieri; Dragan Jevremovic; Morie A. Gertz; Martha Q. Lacy; Francis K. Buadi; David Dingli; Eli Muchtar; Amie L. Fonder; Suzanne R. Hayman; Miriam A. Hobbs; Wilson I. Gonsalves; Rahma Warsame; Taxiarchis V. Kourelis; Yi Lisa Hwa; Prashant Kapoor; Nelson Leung; Ronald S. Go; Robert A. Kyle; S. Vincent Rajkumar; Shaji K. Kumar

doi:10.1182/bloodadvances.2018024794

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma

Mohammed A. Aljama, M. Hasib Sidiqi, Arjun Lakshman, Angela Dispenzieri, Dragan Jevremovic, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, David Dingli, Eli Muchtar, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Wilson I. Gonsalves, Rahma Warsame, Taxiarchis V. Kourelis, Yi Lisa Hwa, Prashant Kapoor, Nelson Leung, Ronald S. GoRobert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (.0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P 5 .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P, .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.

Original language	English (US)
Pages (from-to)	3149-3154
Number of pages	6
Journal	Blood Advances
Volume	2
Issue number	22
DOIs	https://doi.org/10.1182/bloodadvances.2018024794
State	Published - Nov 27 2018

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2018024794

Cite this

Aljama, M. A., Hasib Sidiqi, M., Lakshman, A., Dispenzieri, A., Jevremovic, D., Gertz, M. A., Lacy, M. Q., Buadi, F. K., Dingli, D., Muchtar, E., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Gonsalves, W. I., Warsame, R., Kourelis, T. V., Hwa, Y. L., Kapoor, P., Leung, N., ... Kumar, S. K. (2018). Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Advances, 2(22), 3149-3154. https://doi.org/10.1182/bloodadvances.2018024794

Aljama, MA, Hasib Sidiqi, M, Lakshman, A, Dispenzieri, A, Jevremovic, D, Gertz, MA , Lacy, MQ, Buadi, FK, Dingli, D, Muchtar, E, Fonder, AL, Hayman, SR, Hobbs, MA, Gonsalves, WI, Warsame, R, Kourelis, TV, Hwa, YL, Kapoor, P, Leung, N, Go, RS, Kyle, RA, Vincent Rajkumar, S & Kumar, SK 2018, 'Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma', Blood Advances, vol. 2, no. 22, pp. 3149-3154. https://doi.org/10.1182/bloodadvances.2018024794

@article{41f57bf9ba984aaa8496b428245c656a,

title = "Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma",

abstract = "The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (.0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P 5 .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P, .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.",

author = "Aljama, {Mohammed A.} and {Hasib Sidiqi}, M. and Arjun Lakshman and Angela Dispenzieri and Dragan Jevremovic and Gertz, {Morie A.} and Lacy, {Martha Q.} and Buadi, {Francis K.} and David Dingli and Eli Muchtar and Fonder, {Amie L.} and Hayman, {Suzanne R.} and Hobbs, {Miriam A.} and Gonsalves, {Wilson I.} and Rahma Warsame and Kourelis, {Taxiarchis V.} and Hwa, {Yi Lisa} and Prashant Kapoor and Nelson Leung and Go, {Ronald S.} and Kyle, {Robert A.} and {Vincent Rajkumar}, S. and Kumar, {Shaji K.}",

note = "Publisher Copyright: {\textcopyright} 2018 by The American Society of Hematology",

year = "2018",

month = nov,

day = "27",

doi = "10.1182/bloodadvances.2018024794",

language = "English (US)",

volume = "2",

pages = "3149--3154",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "22",

}

TY - JOUR

T1 - Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma

AU - Aljama, Mohammed A.

AU - Hasib Sidiqi, M.

AU - Lakshman, Arjun

AU - Dispenzieri, Angela

AU - Jevremovic, Dragan

AU - Gertz, Morie A.

AU - Lacy, Martha Q.

AU - Buadi, Francis K.

AU - Dingli, David

AU - Muchtar, Eli

AU - Fonder, Amie L.

AU - Hayman, Suzanne R.

AU - Hobbs, Miriam A.

AU - Gonsalves, Wilson I.

AU - Warsame, Rahma

AU - Kourelis, Taxiarchis V.

AU - Hwa, Yi Lisa

AU - Kapoor, Prashant

AU - Leung, Nelson

AU - Go, Ronald S.

AU - Kyle, Robert A.

AU - Vincent Rajkumar, S.

AU - Kumar, Shaji K.

PY - 2018/11/27

Y1 - 2018/11/27

N2 - The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (.0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P 5 .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P, .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.

AB - The plasma cell proliferative index (PCPI), determined by a slide technique or by flow cytometry, detects cells in the S phase of the cell cycle and is a useful prognostic tool in patients with plasma cell disorders such as multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic effect of PCPI in 306 patients with smoldering multiple myeloma (SMM). Seventy-nine (26%) patients had an elevated PCPI (.0.5). An elevated PCPI predicted an inferior time to progression (median, 3.0 vs 7.1 years for those with a low PCPI; P 5 .0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI (49% vs. 20%; P, .0001). PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow-up and consideration of early intervention trials.

UR - http://www.scopus.com/inward/record.url?scp=85056940469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056940469&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018024794

DO - 10.1182/bloodadvances.2018024794

M3 - Article

C2 - 30463914

AN - SCOPUS:85056940469

SN - 2473-9529

VL - 2

SP - 3149

EP - 3154

JO - Blood Advances

JF - Blood Advances

IS - 22

ER -

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this